全文获取类型
收费全文 | 2503篇 |
免费 | 396篇 |
国内免费 | 81篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 105篇 |
妇产科学 | 26篇 |
基础医学 | 527篇 |
口腔科学 | 105篇 |
临床医学 | 354篇 |
内科学 | 589篇 |
皮肤病学 | 63篇 |
神经病学 | 62篇 |
特种医学 | 37篇 |
外科学 | 261篇 |
综合类 | 313篇 |
预防医学 | 44篇 |
眼科学 | 22篇 |
药学 | 248篇 |
中国医学 | 49篇 |
肿瘤学 | 160篇 |
出版年
2024年 | 11篇 |
2023年 | 66篇 |
2022年 | 71篇 |
2021年 | 162篇 |
2020年 | 128篇 |
2019年 | 144篇 |
2018年 | 119篇 |
2017年 | 135篇 |
2016年 | 133篇 |
2015年 | 116篇 |
2014年 | 150篇 |
2013年 | 174篇 |
2012年 | 107篇 |
2011年 | 111篇 |
2010年 | 91篇 |
2009年 | 71篇 |
2008年 | 91篇 |
2007年 | 88篇 |
2006年 | 71篇 |
2005年 | 90篇 |
2004年 | 95篇 |
2003年 | 78篇 |
2002年 | 63篇 |
2001年 | 67篇 |
2000年 | 67篇 |
1999年 | 56篇 |
1998年 | 64篇 |
1997年 | 49篇 |
1996年 | 42篇 |
1995年 | 31篇 |
1994年 | 27篇 |
1993年 | 36篇 |
1992年 | 22篇 |
1991年 | 23篇 |
1990年 | 13篇 |
1989年 | 14篇 |
1988年 | 19篇 |
1987年 | 8篇 |
1986年 | 12篇 |
1985年 | 10篇 |
1984年 | 11篇 |
1983年 | 5篇 |
1982年 | 7篇 |
1981年 | 7篇 |
1980年 | 10篇 |
1979年 | 6篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1972年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有2980条查询结果,搜索用时 15 毫秒
61.
Amanda H. Anderson Dawei Xie Xue Wang Robin L. Baudier Paula Orlandi Lawrence J. Appel Laura M. Dember Jiang He John W. Kusek James P. Lash Sankar D. Navaneethan Akinlolu Ojo Mahboob Rahman Jason Roy Julia J. Scialla James H. Sondheimer Susan P. Steigerwalt F. Perry Wilson Raymond R. Townsend 《American journal of kidney diseases》2021,77(1):56-73.e1
62.
63.
64.
65.
66.
Qi Qiao Xiong Liu Ting Yang Kexin Cui Li Kong Conglian Yang Zhiping Zhang 《药学学报(英文版)》2021,11(10):3060-3091
Acute respiratory distress syndrome (ARDS) is characterized by the severe inflammation and destruction of the lung air–blood barrier, leading to irreversible and substantial respiratory function damage. Patients with coronavirus disease 2019 (COVID-19) have been encountered with a high risk of ARDS, underscoring the urgency for exploiting effective therapy. However, proper medications for ARDS are still lacking due to poor pharmacokinetics, non-specific side effects, inability to surmount pulmonary barrier, and inadequate management of heterogeneity. The increased lung permeability in the pathological environment of ARDS may contribute to nanoparticle-mediated passive targeting delivery. Nanomedicine has demonstrated unique advantages in solving the dilemma of ARDS drug therapy, which can address the shortcomings and limitations of traditional anti-inflammatory or antioxidant drug treatment. Through passive, active, or physicochemical targeting, nanocarriers can interact with lung epithelium/endothelium and inflammatory cells to reverse abnormal changes and restore homeostasis of the pulmonary environment, thereby showing good therapeutic activity and reduced toxicity. This article reviews the latest applications of nanomedicine in pre-clinical ARDS therapy, highlights the strategies for targeted treatment of lung inflammation, presents the innovative drug delivery systems, and provides inspiration for strengthening the therapeutic effect of nanomedicine-based treatment. 相似文献
67.
《Scandinavian cardiovascular journal : SCJ》2013,47(3-4):141-148
Although upregulation of CD11b/CD18 receptor, i.e. activation of neutrophils and monocytes, during cardiopulmonary bypass is well documented, the duration of the active state after uncomplicated operation is less understood. We therefore investigated CD11b expression of phagocytes in blood samples collected 2-4, 24, 48 and 72 h after coronary artery bypass grafting. CD11b expression on neutrophils was significantly elevated at 2-4 and 24 hours after operation as compared with baseline. On monocytes, expression peaked at 24 h and returned to baseline by 72 h. Because CD11b is a sensitive marker, effects of different sampling techniques on its expression were also studied. CD11b expression was similar in samples collected with a syringe from arterial or central venous catheter or with open technique from cubital vein. On neutrophils from healthy subjects, sampling with syringe caused small (10%) but statistically significant increase of expression. We conclude that activated neutrophils disappear from circulation within hours after CABG surgery while activated monocytes may continue circulating for 2-3 days, and that CD11b sampling can be done with a syringe. 相似文献
68.
Junko Daito Yoshinori Harada Ping Dai Yoshihisa Yamaoka Risa Tamagawa-?Mineoka Norito Katoh Tetsuro Takamatsu 《ACTA HISTOCHEMICA ET CYTOCHEMICA》2014,47(2):67-74
Activated platelets form platelet–leukocyte aggregates in the circulation in inflammatory diseases. We investigated whether activated platelets in inflamed skin tissues are phagocytized and removed by neutrophils. To investigate the kinetics of platelets and neutrophils, we immunohistochemically examined the spatiotemporal distribution of them in a murine model of 2,4,6-trinitro-1-chlorobenzene (TNCB)-induced dermatitis by using confocal and structured illumination microscopy. Four hours after elicitation, aggregates of CD41-positive platelets were adhered to CD31-positive endothelial cells within the vessels, and CD62P and PF4, markers of activated platelets, were expressed on platelet aggregates. At 8 hour post-elicitation, fragmented CD41-positive platelets were located both inside and outside vessels. Twenty-four hours after elicitation, the number of Ly-6G-positive neutrophils ingesting fragmented CD41-positive platelets outside vessels was increased, and CD62P and PF4 expression on the phagocytosed platelets was no longer observed. Disc-shaped CD41-positive platelets were not found outside vessels at any time during the experiment. Our data revealed that aggregates of activated platelets inside vessels were ingested and removed by neutrophils in the early stage of TNCB-induced dermatitis, suggesting that the process of removal of activated platelets by neutrophils may play an important role not only in the early phase of skin inflammation but also in other types of acute inflammation. 相似文献
69.
70.
《Expert opinion on investigational drugs》2013,22(2):159-167
Innate immune mechanisms respond rapidly to bacterial infection. A key cellular component of the innate immune response is the neutrophil, whose cytoplasmic granules contain a variety of antimicrobial proteins and peptides. Among these is the bactericidal/permeability-increasing protein (BPI), a cationic 55 kDa protein whose selective anti-infective action against Gram-negative bacteria is based on its high (nM) affinity for lipopolysaccharide (LPS, or “endotoxin”). Binding of BPI to Gram-negative bacteria results in growth inhibition, serves as an opsonin that enhances phagocytosis of bacteria and inhibits bacteria-induced inflammatory responses by blocking the interaction of LPS with host pro-inflammatory pathways. Expression of BPI appears to be developmentally regulated as human newborns apparently have lower neutrophil BPI levels than adults. BPI expression has also recently been demonstrated in human epithelial cells where it appears to be inducible by endogenous anti-inflammatory lipids (lipoxins). BPI’s potent anti-endotoxic activity against a broad range of Gram-negative bacterial pathogens is manifest in biological fluids and renders it an attractive template for pharmaceutical development. Indeed, rBPI21, an active recombinant protein derived from human BPI, has proven safe in Phase I human trials, shown promise in Phase II trials and has recently completed a Phase III trial for severe meningococcaemia with apparent benefit. Identification and evaluation of additional disease entities characterised by Gram-negative bacteraemia and/or endotoxaemia as possible targets for BPI therapy continues. 相似文献